Oxurion Receives Transparency Notice from Atlas Special Opportunities LLC

Oxurion Receives Transparency Discover from Atlas (NYSE:) Particular Alternatives LLC

Leuven, Belgium “Might 13, 2024” 7:00 pm CET The Leuven-based biopharmaceutical firm (Euronext Brussels: OXUR) introduced at the moment that it has obtained a transparency notification beneath Belgian transparency laws 1 as follows:

Oxurion obtained a transparency discover from Atlas Particular Alternatives, LLC on Might 9, 2024, indicating that as of Might 2, 2024, it held 1,467,712,295 shares of the then excellent 10,101,777,808 shares and, subsequently, by advantage of the acquisition of voting securities. See attachment 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is creating next-generation, standard-of-care remedies for retinal illnesses. Oxurion is headquartered in Leuven, Belgium. For extra data, please go to www.oxurion.com.

Vital Data Relating to Ahead-Wanting Statements

Sure statements on this press launch could also be deemed to be forward-looking. Such forward-looking statements are based mostly on present expectations and, subsequently, contain and are topic to varied dangers and uncertainties. Accordingly, the Firm can’t assure that such forward-looking statements will materialize and disclaims any obligation to replace or revise any forward-looking statements, whether or not because of new data, future occasions or some other cause. Further data relating to the dangers and uncertainties affecting the enterprise and different elements that would trigger precise outcomes to vary materially from any forward-looking statements is included within the firm’s annual report. This press launch doesn’t represent a suggestion or solicitation to promote or purchase Oxurion securities or property in any jurisdiction. No securities of Oxurion could also be supplied or bought inside the US with out registration beneath the US Securities Act of 1933, as amended, or an exemption therefrom and any relevant U.S. state securities legal guidelines.

For extra data please contact:

____

1. Article 14, paragraph 1, of the “Important Shareholding Disclosure Regulation” promulgated on Might 2, 2007.

attachment1